Serina Therapeutics, Inc. (SER) Research

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

Market snapshot

Symbol
SER
Price
$2.10
Day change
+6.06%
Market cap
$22.7M
P/E ratio
-1.19x
52-week range
1.22-7.92
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Recent news

  • Stock Market Today: S&P 500, Dow Futures Down Ahead Of 'Triple Witching' As Iran Warns Of 'Zero Restraint'—FedEx, Super Micro Computer In Focus

    U.S. stock futures declined on Friday following Thursday's declines. Futures of the major benchmark indices were lower.

  • Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why

    Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.

Peer companies

  • Aligos Therapeutics, Inc. (ALGS)
  • Barinthus Biotherapeutics plc (BRNS)
  • CEL-SCI Corporation (CVM)
  • Genenta Science S.p.A. (GNTA)
  • Grace Therapeutics, Inc. (GRCE)
  • INmune Bio, Inc. (INMB)
  • Jupiter Neurosciences, Inc. (JUNS)
  • Skye Bioscience, Inc. (SKYE)

Recent insider activity

  • WILSON KAREN J — P-Purchase (5000 shares) on 2026-06-12
  • WILSON KAREN J — P-Purchase (5100 shares) on 2026-06-11
  • LEDGER STEVEN A — A-Award (10100 shares) on 2026-05-26
  • Tenjarla Srini — A-Award (85558 shares) on 2026-05-21
  • LEDGER STEVEN A — A-Award (380825 shares) on 2026-05-21

Open Serina Therapeutics, Inc. (SER) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.